Valye reports for unlimited access

Kopin Corporation, incorporated in 1984 and headquartered in Massachusetts, specializes in innovative microdisplay technologies and optical systems. Its product portfolio includes AMLCDs, LCOS, OLED, and emerging MicroLED displays, complemented by optics, electronics, and housings forming Application Specific Optical Solutions (ASOS). The company is developing a fifth-generation NeuralDisplay™ microdisplay with AI-enabled backplane technology. Kopin serves defense, industrial, medical, and consumer sectors globally, with manufacturing and design operations spread across the USA, Asia, and Europe. Its offerings range from individual display components to integrated headsets and subsystems designed for rugged environments. Revenue streams include product sales and customer-funded development contracts, primarily for U.S. defense programs. Kopin holds over 200 patents, providing a significant intellectual property advantage. The company reported Q2 2026 revenues of $1.27 million and a net loss of $2.9 million, with a strong liquidity position as of June 27, 2026 [S1][S2].

AECOM is a leading global provider of professional infrastructure consulting and advisory services, serving governments, businesses, and organizations worldwide. The company offers a comprehensive suite of services including advisory, planning, consulting, architectural and engineering design, construction and program management, and real estate investment and development. It operates through three main segments: Americas, International, and AECOM Capital. The Americas and International segments focus on fee-based services across major infrastructure markets such as transportation, water, environmental, and energy. AECOM Capital invests in and develops real estate projects, often partnering with other investors. The company emphasizes technical expertise across multiple engineering disciplines and invests in digital and AI capabilities to enhance service delivery. Clients include a diverse mix of public and private entities, with no single client representing a dominant revenue source. The company reported approximately $16.1 billion in revenue for fiscal 2025 and employs around 51,000 people globally [S1].

TRG Latin America Acquisitions Corp. is a special purpose acquisition company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Incorporated in the Cayman Islands, the company completed its IPO in February 2026, raising gross proceeds of $200 million. The company’s units, Class A ordinary shares, and rights are listed on the Nasdaq Global Market. The company’s business model centers on identifying and consummating an initial business combination within a specified timeframe, currently set to February 27, 2028, subject to possible extension with shareholder approval. The company’s financial disclosures indicate a strong liquidity position as of June 30, 2026, with current assets significantly exceeding current liabilities. The company’s operations and financial results are limited to its formation, capital raising, and administrative activities to date, with no disclosed revenue or operating segments.

WRAP TECHNOLOGIES, INC. develops and markets integrated non-lethal public safety solutions designed to provide law enforcement and related agencies with tools, training, and tactics to manage encounters proactively and safely. The company’s flagship product, BolaWrap, is a handheld device that deploys a Kevlar tether to entangle subjects, offering a non-pain-compliance alternative to traditional force options. WRAP complements its hardware with immersive virtual reality training (Wrap Reality), digital training subscriptions (WrapTactics), and body-worn camera and digital evidence management solutions (WrapVision). The company has expanded into defense and homeland security markets through its subsidiary Wrap Federal, LLC, and is developing counter-unmanned aircraft system technologies leveraging its tether deployment expertise. WRAP’s sales efforts focus on U.S. federal, state, and local law enforcement agencies, as well as international markets, with a strategy to build integrated, multi-product customer relationships. The company’s financial disclosures show modest revenue with ongoing operating losses and strong liquidity as of mid-2026.

Inuvo, Inc. specializes in generative artificial intelligence for modeling media audiences, leveraging a proprietary large language model called IntentKey® that identifies consumer intent rather than identity. The company provides AI-driven data and advertising technology solutions designed for the evolving advertising landscape, particularly as autonomous AI agents increasingly handle media planning and execution. Inuvo's technology suite includes IntentKey®, IntentPath, and Ranger, which enable precision audience discovery, real-time intent visualization, and ad creative quality assurance. The company serves clients through two main channels: Agencies & Brands and Platform integrations with large advertising consolidators. Inuvo holds a portfolio of patents and maintains significant relationships with major advertising spenders such as Yahoo! and Google. The company has experienced a decline in its Legacy Search business due to market changes but is adapting through operational and compliance initiatives. As of mid-2026, Inuvo reported revenues of $7.54 million for the quarter, with a net loss and liquidity challenges reflected in a current ratio below 1.0.

Mineralys Therapeutics, Inc. focuses on developing therapies for diseases driven by dysregulated aldosterone, primarily hypertension and associated comorbidities such as chronic kidney disease and obstructive sleep apnea. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed to reduce aldosterone production by inhibiting the CYP11B2 enzyme. The company has completed six clinical trials, including pivotal Phase 3 and Phase 2 studies, demonstrating clinically meaningful reductions in systolic blood pressure and a favorable safety profile. The FDA accepted the NDA submission for lorundrostat in December 2025, with a target action date in December 2026. Mineralys also conducts ongoing trials to explore lorundrostat's benefits in comorbid conditions and collects long-term safety data through an open-label extension trial. The company reported strong liquidity with over $660 million in current assets as of June 30, 2026, but also disclosed significant net losses and risks related to its indebtedness and regulatory approval process.

Auburn National Bancorporation, Inc. is a bank holding company controlling AuburnBank, which operates primarily in East Alabama including Lee County. The company has a long history dating back to 1907 and is regulated by the Federal Reserve and Alabama banking authorities. Its business model centers on traditional banking services including loan origination, deposit gathering, and mortgage lending. The company pursues organic growth and may consider acquisitions, facing competition from other banks, credit unions, and nonbank financial institutions. Technological investments aim to improve customer service and operational efficiency while managing cybersecurity and compliance risks. The company’s financial performance is influenced by local and general economic conditions, interest rates, and regulatory environment. It maintains strong capital adequacy and liquidity positions. Recent financial results show growth in earnings, net interest income, and loan balances, with stable dividend payments.

Firefly Aerospace Inc. is a publicly traded aerospace company focused on space launch services and related technologies. The company engages in government and commercial contracts, including significant involvement with NASA for lunar missions. Firefly Aerospace has recently expanded its capital base through a public offering and maintains a revolving credit facility to support operations. The company is actively scaling production and expanding its operational footprint under new executive leadership.

Spartacus Acquisition Corp. II is a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands in November 2025. Its business model is to raise capital through an IPO and then identify and consummate a Business Combination with one or more target companies in any industry. The company completed its IPO in February 2026, issuing 23 million Public Units and raising $230 million, which is held in a Trust Account. The company has not yet selected a target and has no operating revenues. The management team has extensive experience in technology, media, and telecommunications sectors and aims to leverage its network and operational expertise to identify and execute a Business Combination within 24 months. The company’s structure includes Founder Shares held by officers and directors, which convert into Class A Ordinary Shares upon Business Combination, potentially diluting public shareholders. The company’s financial position as of June 30, 2026, shows strong liquidity and positive net income, reflecting organizational activities and investment income rather than operating results.

Pixelworks, Inc. is a technology company specializing in content creation, video delivery, and display processing solutions aimed at providing authentic and high-quality visual experiences across various screens. After selling its semiconductor business in early 2026, Pixelworks shifted its focus exclusively to cinematic visualization solutions, primarily through its TrueCut Motion platform. This platform offers filmmakers tools for motion grading to preserve creative intent, along with certification and licensing services for distributors and display manufacturers. The company holds a significant intellectual property portfolio with 56 issued patents and 6 pending applications related to video processing technologies. Pixelworks operates with a lean workforce of approximately 23 employees post-sale and generates revenue mainly from licensing and services tied to the TrueCut Motion platform. The company reported modest revenue and a net loss in the second quarter of 2026 but maintains strong liquidity with a current ratio above 35 [S1][S2].

KLX Energy Services Holdings, Inc. (KLXE) provides diversified oilfield services primarily to independent major oil and gas companies operating onshore in the United States. The company was formed through the combination of several regional oilfield service companies and became publicly traded following a spin-off in 2018. KLXE operates in three main geographic segments covering major U.S. basins and offers a comprehensive suite of services including drilling, completion, production, and intervention activities. Its product offerings include hydraulic fracturing equipment and downhole tools. The company emphasizes technical expertise and in-house research and development to deliver engineered solutions that address complex well requirements. KLXE's business is cyclical and closely tied to oil and gas industry activity and commodity price fluctuations. The company maintains a significant capital base with ongoing investments in maintenance and growth capital expenditures. It is subject to financial covenants under its debt agreements and has access to equity capital markets through an Equity Distribution Agreement.

Abony Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in November 2025. It was formed to identify and complete a business combination with one or more target companies, focusing on sectors such as defense technology, advanced computing, software, and media. The company completed its initial public offering in February 2026, raising gross proceeds of $230 million plus a private placement of $6.95 million. The proceeds are held in a trust account to be used for the initial business combination. The management team, led by CEO Lorne Abony and CFO/COO Leo Kofman, brings extensive experience in scaling public companies, capital markets, and SPAC transactions. The company has not yet engaged in operations or generated revenues and plans to complete a business combination within 24 months of the IPO, with possible extensions subject to shareholder approval. The company prioritizes acquisition targets with experienced management, strong market positions, and growth potential.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing product candidates primarily for rare diseases such as Prader-Willi Syndrome. Its lead candidate, ARD-101, is an oral small-molecule agonist targeting gut receptors to address hyperphagia. The company has no products approved for commercial sale and has focused on clinical development, intellectual property, and organizational growth since its inception in 2017. It relies on third parties for clinical trials and manufacturing. The company has established a subsidiary, Ardia, to advance its dermatology pipeline. Aardvark faces typical biopharmaceutical risks including regulatory approval challenges, clinical trial uncertainties, and capital requirements.

Sanara MedTech Inc. develops and commercializes surgical technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market. Its product portfolio includes soft tissue repair products such as CellerateRX Surgical Powder, a hydrolyzed collagen aiding surgical wound healing, and BIASURGE Advanced Surgical Solution, a sterile wound irrigation product with antimicrobial properties. Bone fusion products include BiFORM Bioactive Moldable Matrix and ALLOCYTE Plus Advanced Viable Bone Matrix. The company’s strategy centers on the "Prepare, Promote and Protect" framework, guiding product development and commercialization efforts. Sanara MedTech has discontinued its post-acute value-based wound care services segment (Tissue Health Plus) to focus exclusively on surgical products. The company sells primarily in the U.S. through a network of surgical specialty distributors and company representatives. It relies on contract manufacturers for production and does not face reimbursement risk as its products are sold as Diagnosis Related Group products within operating rooms. The company has a pipeline of innovative products and partnerships, including a planned U.S. launch of OsStic BioAdhesive. As of 2025, it had contracts with over 4,000 hospitals and a salesforce of 40 field representatives. The company is subject to competition from larger medical device companies and operates under comprehensive regulatory requirements.

Rithm Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) formed to effect a business combination. It completed its IPO in February 2025, issuing units consisting of Class A ordinary shares and redeemable warrants. The company holds substantial cash in a Trust Account reserved for the initial business combination or liquidation. It incurs administrative expenses and earns interest income on its cash balances. The company has governance agreements with its sponsor, including indemnification and registration rights. It is classified as an emerging growth company and smaller reporting company, with no operating business or revenue disclosed to date.

Broadwind, Inc. manufactures precision structures, equipment, and components primarily for power generation and critical infrastructure markets in the U.S. It operates three segments: Heavy Fabrications, which produces steel wind towers and pressure reducing systems; Gearing, which supplies gearboxes and precision machined components to diverse industrial markets; and Industrial Solutions, which offers supply chain and assembly services mainly for natural gas turbine markets. The company has focused on diversifying its customer base and product offerings, reducing wind energy sales concentration from 70% in 2020 to 51% in 2025, and decreasing reliance on its top five customers. It maintains a production facility in Abilene, Texas, with capacity to produce approximately 220 wind towers annually. Broadwind faces competition from domestic and international manufacturers and operates in a regulatory environment influenced by U.S. tax credits and infrastructure legislation. The company reported a net loss in Q2 2026 and maintains liquidity with a current ratio of 2.72 as of June 30, 2026.

Mount Logan Capital Inc. operates as an alternative asset management and insurance solutions company with two primary segments: Asset Management and Insurance Solutions. The Asset Management segment focuses on private credit investments across various strategies including senior secured lending, specialty finance, and venture lending, managing approximately $2.0 billion in assets as of mid-2026. It generates recurring fee-related earnings from management fees, performance fees, and related income. The Insurance Solutions segment is conducted through Ability Insurance Company, which reinsures annuity products such as multi-year guaranteed annuities (MYGA) and manages a runoff book of long-term care policies. Ability's investment portfolio includes high-grade fixed income and floating rate assets, with risk managed through asset-liability matching and hedging. The company completed a business combination in 2025, enhancing its capital base and public market presence. Mount Logan's growth strategy involves expanding AUM, increasing reinsurance flows, and pursuing acquisitions and partnerships to diversify and scale its offerings. The company manages liquidity through cash reserves, credit facilities, and asset sales, with primary uses including business growth, operating expenses, policyholder payments, debt service, and share repurchases.

INNEOVA Holdings Ltd is a Cayman Islands holding company with subsidiaries operating mainly in Singapore and Malaysia. The company conducts its operations through three segments: On-Highway Business supplying genuine and aftermarket automotive spare parts; Off-Highway Business supplying industrial spare parts with a focus on filtration products for sectors such as marine, energy, mining, construction, agriculture, and oil and gas; and Engineering Services providing system lifecycle analysis and turnkey solutions across multiple sectors including transport and healthcare. The company sources products from OEMs and global premium brands and also develops in-house brands. It emphasizes quality control through strict protocols and ISO certifications. Customers are primarily resellers, distributors, workshops, and fleet owners, with revenue geographically split between domestic and export markets. The company reported total revenue of approximately $58.4 million for 2025, with a net loss and modest liquidity ratios.

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company formed in 2018, focused on developing novel therapies for immunological indications. Its lead product candidate, mivocabtagene autoleucel (miv-cel), is in clinical development for diseases including rheumatoid arthritis and stiff person syndrome. The company has no approved products or commercial revenue and depends on successful clinical development and regulatory approval of its candidates. Kyverna relies on third-party contract manufacturers and suppliers for production and has entered into agreements to secure clinical and commercial supply. The company has incurred significant net losses and maintains a secured loan agreement with Oxford Finance LLC, which places restrictions on its financial flexibility. Kyverna continues to invest in clinical trials, regulatory submissions, and launch readiness activities while managing risks related to clinical development, regulatory approval, supply chain, intellectual property, and capital requirements.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company with a focus on presbyopia treatment through its lead product, VIZZ (aceclidine ophthalmic solution) 1.44%. VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia in adults, approved in July 2025 and commercially launched in the U.S. in August 2025. The company’s prior operations centered on product development, capital raising, and commercialization preparation. VIZZ became broadly available in retail pharmacies by November 2025 and expanded access via a telehealth platform in July 2026. LENZ depends solely on VIZZ for its business and has no other product candidates in development. The company has established license agreements with partners to commercialize VIZZ in multiple international territories, including Australia, New Zealand, Greater China, South Korea, Southeast Asia, Canada, and the Middle East. LENZ contracts with third-party manufacturers for production and faces risks related to supply, regulatory compliance, and intellectual property protection. The company has incurred significant net losses since inception and continues to invest in commercialization infrastructure and marketing efforts to drive product adoption.

Fold Holdings, Inc. operates in the financial technology sector with a focus on Bitcoin treasury management and related financial services. The company has publicly disclosed its financial position and operational results through SEC filings and earnings calls. As of mid-2026, Fold maintains liquidity with a current ratio of 1.84 and cash ratio of 1.34, supported by cash and current assets exceeding current liabilities. The company reported a net loss in the most recent quarter, reflecting ongoing investment or operational costs. Fold has secured a significant equity purchase facility to enhance its Bitcoin treasury, indicating a strategic emphasis on cryptocurrency assets.

EBR Systems, Inc. develops and commercializes the WiSE CRT System, a novel leadless cardiac pacing device designed to provide cardiac resynchronization therapy without the complications associated with traditional lead-based systems. The system uses ultrasound energy to stimulate the left ventricle and requires a co-implanted device for right ventricular pacing. The company received FDA approval in April 2025 and has initiated a phased commercial launch in the U.S., with plans for international expansion pending regulatory approvals. The company is conducting a post-approval study to monitor safety and effectiveness and is investing in sales and marketing to drive adoption.

Purple Innovation, Inc. is a sleep products company focused on delivering innovative comfort solutions through proprietary and patented Hyper-Elastic Polymer gel technology. Founded as a digitally-native vertical brand, Purple has expanded into brick-and-mortar retail with 55 showrooms across the U.S. as of end 2025. The company markets and sells its products via direct-to-consumer channels including e-commerce and showrooms, as well as wholesale through national and regional retail partners. Purple's product portfolio includes mattresses, pillows, cushions, bases, and sheets, all designed to provide pressure relief, temperature neutrality, responsiveness, and durability. The company emphasizes vertical integration with in-house design, development, manufacturing, and proprietary equipment, enabling rapid innovation and scale. Recent acquisitions have expanded Purple's luxury mattress offerings. The company reported $98.27 million in revenue and a net loss of $3.23 million for Q2 2026, with liquidity ratios reflecting a current ratio of 0.52 and cash ratio of 0.11 as of June 30, 2026.

Golden Growers Cooperative is a value-added agricultural cooperative formed in 1994 to enable its members to gain additional value from corn through processing into products such as corn sweeteners. The Cooperative owns a 50% interest in ProGold LLC, which owns a corn wet-milling facility in Wahpeton, North Dakota. ProGold leases the facility to Cargill, which operates it and pays lease payments that generate income for the Cooperative. The Cooperative's members, primarily from Minnesota, North Dakota, and South Dakota, are contractually obligated to deliver corn annually to the facility. The Cooperative operates through contractual relationships rather than owning physical assets. Income and losses are allocated to members based on corn delivery volumes and methods. The Cooperative approved a Plan of Liquidation and Dissolution in 2025, including selling its ProGold interest to Cargill after the lease ends in 2026.

Momentus Inc. operates in the commercial space sector, providing satellites, satellite buses, components, and a range of space transportation and infrastructure services. Its offerings include last-mile satellite transportation using Orbital Service Vehicles (OSVs) like Vigoride, which has been demonstrated in multiple missions. The company develops innovative technologies such as the water-propellant Microwave Electrothermal Thruster and Tape Spring Solar Array, aiming to offer cost-effective and flexible satellite solutions. Momentus also plans to provide in-orbit servicing capabilities including refueling, inspection, and debris removal. It maintains partnerships with leading launch providers and holds a portfolio of patents supporting its technology. The company has raised capital through public offerings to support its growth and operations.

Ambiq Micro, Inc. develops and sells ultra-low power semiconductor solutions focused on enabling AI compute at the edge, where power constraints are most severe. Its proprietary SPOT® platform reduces power consumption by two to five times compared to conventional designs without requiring costly manufacturing processes. The company offers integrated hardware and software solutions including SoCs that support AI processing, sensing, security, and connectivity. Key markets include wearable devices, AR/VR, digital health, security, agriculture, and industrial automation. Ambiq’s customers rely on its technology to extend battery life while supporting advanced AI features such as speech recognition and image processing. The company’s sales efforts prioritize geographies including the U.S., Europe, and Asia (excluding Mainland China) due to geopolitical and competitive factors. Ambiq completed its IPO in July 2025 and a follow-on offering in January 2026, raising significant capital to support operations and growth. The company’s financial performance reflects ongoing investments in R&D and sales, with net sales of $72.5 million and net losses of $36.5 million in 2025. Ambiq’s business is subject to risks including customer concentration, supply chain dependencies, geopolitical tensions, and the cyclical nature of the semiconductor industry.

PLAYSTUDIOS, Inc. develops and operates free-to-play mobile and online social gaming applications, many featuring loyalty programs that offer real-world rewards through partnerships. The company’s games are distributed on major digital platforms such as Apple App Store, Google Play Store, Amazon Appstore, and Facebook. Revenue is primarily derived from in-game purchases of virtual currency and advertising. The company’s operations are organized into two segments: playGAMES, which includes the mobile gaming portfolio, and playAWARDS, which manages the loyalty and marketing platform. As of mid-2026, PLAYSTUDIOS maintains a strong liquidity position with cash and equivalents exceeding $100 million and a current ratio near 3. The company reported net losses in recent quarters, with revenues showing a modest decline year-over-year. The company’s board and executive team have extensive experience in gaming, technology, and finance sectors. PLAYSTUDIOS recently transitioned its Nasdaq listing to the Capital Market, receiving an extended period to meet minimum bid price requirements.

Sentient Brands Holdings Inc. is a Nevada-based consumer packaged goods company focused on wellness, sustainability, and emergency preparedness. It operates through wholly and majority-owned subsidiaries that manufacture and distribute a portfolio of premium and functional products including natural sodas, premium vodka, European wine and food, and emergency water and meal kits. The company’s subsidiaries include AIG-F&B, which handles food, beverage, and wellness products; Aqua Emergency, specializing in emergency preparedness products with exclusive American Red Cross licensing; and Wyoming Bears, a distributor supplying convenience stores and big box retailers domestically and internationally. The company’s growth strategy centers on acquisition-driven expansion, operational excellence, and leveraging brand equity and licensing relationships. Marketing efforts include social media, influencer campaigns, and traditional media. The company faces intense competition from better-capitalized peers in the CPG sector. Financially, the company reported its first consolidated revenues in 2025 and continues to work on restructuring and capitalization initiatives. As of mid-2026, the company shows limited liquidity and ongoing net losses, reflecting its early-stage growth and acquisition integration phase.

EQUATOR Beverage Company, formerly MOJO Organics, Inc., is a beverage company headquartered in Jersey City, New Jersey. It produces a portfolio of premium, natural hydration beverages including MOJO Coconut Water and various flavored and sparkling coconut water products. The company’s products are certified Non-GMO and USDA Organic, targeting consumers seeking functional, clean-label, and premium beverage options. EQUATOR emphasizes sustainability through eco-friendly, recyclable packaging and plant-based ingredients. The company distributes its products across North America, the Caribbean, and Bermuda through third-party distributors and retail channels. EQUATOR operates with a lean internal team supplemented by outsourced manufacturing, logistics, sales, and professional services. It sells over 8 million units annually and focuses on disciplined growth and supply chain stability.

Chain Bridge Bancorp, Inc. operates as a bank holding company with its primary operations conducted through Chain Bridge Bank, N.A., a nationally chartered commercial bank with fiduciary powers. The company offers a comprehensive suite of banking and trust services including deposits, treasury management, payments, commercial and consumer lending, residential mortgage financing, trust and estate administration, wealth management, and asset custody. The bank operates a branchless model, providing services primarily through digital platforms and a centralized headquarters, enabling nationwide reach with lower overhead costs. The company’s client base includes businesses, non-profit organizations, political organizations, and individuals, with a notable focus on political organizations and related entities, which contribute significantly to deposit balances and transaction volumes. The bank’s lending portfolio is concentrated in the Washington, D.C. metropolitan area, with a focus on residential and commercial real estate loans. The company emphasizes liquidity, asset quality, and financial strength, maintaining a conservative balance sheet with a significant portion of assets in cash, cash equivalents, and investment-grade securities. The treasury management system supports high transaction volumes and complex organizational structures, tailored to meet the needs of commercial clients with sophisticated banking requirements. The company faces competition from large national and regional banks, as well as fintech and other financial institutions, but differentiates itself through personalized service and technology-driven solutions.

Osprey Bitcoin Trust is an exchange-traded fund designed to provide investors with exposure to Bitcoin price performance through shares listed on Nasdaq under the symbol OBTC. The Trust holds Bitcoin as its primary asset, managed and custodied by specialized entities. It operates as a passive investment vehicle, aiming to track the CME CF Bitcoin Reference Rate - New York Variant, less expenses and liabilities. The Trust issues and redeems shares in baskets based on Bitcoin quantities, allowing investors to gain exposure without directly owning or managing Bitcoin wallets. The Trust is governed by a Trust Agreement and managed by Osprey Funds, LLC, which receives a management fee. It is not registered as an investment company or commodity pool and does not use leverage or derivatives.

Magnolia Bancorp, Inc. was incorporated in May 2024 as part of the conversion of Mutual Savings and Loan Association from a mutual to a stock form of organization, completed in January 2025. The company is the holding company for Mutual Savings, which operates primarily in Jefferson and St. Tammany Parishes in Louisiana. Magnolia Bancorp does not own property but uses the facilities and staff of Mutual Savings. The company’s business model centers on originating and retaining fixed-rate one-to-four family residential mortgage loans, with a small portion of commercial real estate and share loans. It offers fixed-rate loans with terms ranging from 15 to 30 years, including a bi-weekly mortgage program that accelerates equity build-up. The company does not currently offer adjustable-rate or interest-only residential loans except for construction loans, which are structured as construction/permanent loans with fixed rates. Magnolia Bancorp’s loan originations come mainly from repeat customers and referrals. The company is subject to regulation by the OCC and operates in a competitive market with various financial institutions. Financial results for Q2 2026 show a net loss and negative EPS, with limited liquidity data disclosed.

Uwharrie Capital Corp is a financial services company engaged primarily in lending activities, including commercial loans, residential real estate loans, home equity loans, and other real estate construction loans. The company reports detailed financial data through SEC filings, with recent filings indicating solid liquidity and profitability metrics. The company operates without material legal proceedings as of the latest annual report.

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company developing therapies primarily for hematologic cancers and autoimmune diseases. Its lead product candidate, telitacicept, has received regulatory approval in China for the treatment of Sjögren's Disease. The company has raised capital through public offerings and private placements to fund clinical development and pre-commercialization activities. Vor Biopharma maintains strong liquidity as of mid-2026 and has governance structures in place to manage cybersecurity risks. The company is not currently involved in any material legal proceedings.

United-Guardian, Inc. is a specialty ingredients company operating through its Guardian Laboratories division. It manufactures, markets, and develops cosmetic, personal care, sexual wellness ingredients, and healthcare products including pharmaceuticals and medical lubricants. The company emphasizes product innovation, focusing on natural and environmentally friendly raw materials. Its product portfolio includes the Lubrajel line of hydrogels for cosmetic and medical applications, Renacidin pharmaceutical product, and the new Natrajel sexual wellness line. Distribution is global, with key partnerships including Ashland Specialty Ingredients and Brenntag Specialties. The company operates a single business segment and maintains a strong focus on R&D and market expansion.

Future Vision II Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in January 2024. Its business model is to identify and complete a business combination with one or more target companies, primarily focusing on businesses in Asia. The company completed its IPO in September 2024, raising gross proceeds of $57.5 million, which are held in a trust account invested in U.S. government securities. The company has not commenced operations or generated revenues to date and will generate operating revenues only after completing a business combination. The company entered into a merger agreement in January 2026 with MicroTouch Technology Inc., a Hong Kong-based IT services and custom software development company, valuing MicroTouch at $90 million. The merger is subject to customary closing conditions, including SEC approval and shareholder votes. The company’s management team has experience in financial services, accounting, legal, and senior operating roles, with expertise in mergers and acquisitions. The company’s liquidity position as of June 30, 2026, is strong, with cash and equivalents of $1.33 million, short-term investments of $61 million, and a current ratio of 63.05.